Cell-free DNA as a potential biomarker in stroke: a comprehensive review of observational studies

Abstract

Stroke is an abrupt loss of brain function, which is caused by the interruption of blood flow to the brain. Several blood biomarkers have been evaluated for the assessment of stroke severity and outcome. However, their roles remain limited in clinical practice. Circulating cell-free deoxyribonucleic acid (DNA) has emerged as a potential biomarker of stroke, as reported from several animal and human studies. In this study, we aim to review the prognostic values of cell-free DNA in stroke from all relevant cohort studies. The PubMed database was searched using keywords, "cell-free DNA" and "stroke" for relevant articles. Twelve studies (n = 946 patients) are included in the final analysis. While the prognostic values of cell-free DNA in predicting functional outcomes and hospital mortality after different types of stroke were highlighted in many studies, the inconsistency in methods hinders comparability between studies. Overall, the knowledge about the potential prognostic ability of cell-free DNA in stroke remains limited and conflicting. More robust studies with consistent methods are needed.

Keywords

Cell-free DNA / stroke / nucleosome / biomarker

References

[1] DonkorES.Stroke in the 21(st) century: a snapshot of the burden, epidemiology, and quality of life..Stroke Res Treat2018;2018:3238165 PMCID:PMC6288566

[2] DirnaglU,MoskowitzMA.Pathobiology of ischaemic stroke: an integrated view..Trends Neurosci1999;22:391-7

[3] JicklingGC.Blood biomarkers of ischemic stroke..Neurotherapeutics2011;8:349-60 PMCID:PMC3250275

[4] HasanN,BentleyP,SharmaP.Towards the identification of blood biomarkers for acute stroke in humans: a comprehensive systematic review..Br J Clin Pharmacol2012;74:230-40 PMCID:PMC3630743

[5] MiaoY.Potential serum biomarkers in the pathophysiological processes of stroke..Expert Rev Neurother2014;14:173-85 PMCID:PMC3939679

[6] SaengerAK.Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment..Clin Chem2010;56:21-33

[7] RanucciR.Cell-free DNA: applications in different diseases..Methods Mol Biol2019;1909:3-12

[8] WangW,MaG,ZhuJ.Characterization of the release and biological significance of cell-free DNA from breast cancer cell lines..Oncotarget2017;8:43180-91 PMCID:PMC5522137

[9] KustanovichA,PeretzT.Life and death of circulating cell-free DNA..Cancer Biol Ther2019;20:1057-67 PMCID:PMC6606043

[10] VajpeyeeA,VajpeyeeM.Cell free DNA: a novel predictor of neurological outcome after intravenous thrombolysis and/or mechanical thrombectomy in acute ischemic stroke patients..Neurointervention2018;13:13-9 PMCID:PMC5847885

[11] BustamanteA,MacherHC,GiraltD.Circulating cell-free DNA is a predictor of short-term neurological outcome in stroke patients treated with intravenous thrombolysis..J Circ Biomark2016;5:1849454416668791 PMCID:PMC5548318

[12] BronkhorstAJ,AucampJ,du PlessisL.Characterization of the cell-free DNA released by cultured cancer cells..Biochim Biophys Acta2016;1863:157-65

[13] JahrS,EnglischS,FackelmayerFO.DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells..Cancer Res2001;61:1659-65

[14] ZhivotoskyB.Assessment of apoptosis and necrosis by DNA fragmentation and morphological criteria..Curr Protoc Cell Biol2001;18:18.3.1-23

[15] O’ConnellGC,TennantCS,KabbaniY.Circulating extracellular DNA levels are acutely elevated in ischaemic stroke and associated with innate immune system activation..Brain Inj2017;31:1369-75

[16] SandercockP,LindleyRI,CohenG.The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial..Lancet2012;379:2352-63 PMCID:PMC3386495

[17] HanselmanCJ.Timing of tissue plasminogen activator for acute ischemic stroke: outcomes-based recommendations for practice..J Neurosci Nurs2014;46:314-20

[18] SwarupV.Circulating (cell-free) nucleic acids--a promising, non-invasive tool for early detection of several human diseases..FEBS Lett2007;581:795-9

[19] TsaiNW,ChenSD,WangHC.The value of serial plasma nuclear and mitochondrial DNA levels in patients with acute ischemic stroke..Clin Chim Acta2011;412:476-9

[20] RainerTH,LamW,GrahamCA.Comparison of plasma beta-globin DNA and S-100 protein concentrations in acute stroke..Clin Chim Acta2007;376:190-6

[21] VallesJ,SantosMT,TemblJI.Neutrophil extracellular traps are increased in patients with acute ischemic stroke: prognostic significance..Thromb Haemost2017;117:1919-29

[22] VajpeyeeA,VajpeyeeM,PandeyS.Clinical usefulness of cell-free DNA as a prognostic marker in acute ischemic stroke..Neurologist2020;25:11-3

[23] RainerTH,LamW,LamNY.Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke..Clin Chem2003;49:562-9

[24] GeigerS,StieberP,BrueningR.Nucleosomes in serum of patients with early cerebral stroke..Cerebrovasc Dis2006;21:32-7

[25] LamNY,WongLK,LoYM.Plasma DNA as a prognostic marker for stroke patients with negative neuroimaging within the first 24 h of symptom onset..Resuscitation2006;68:71-8

[26] WangHC,LinWC,TsaiNW.The value of serial plasma and cerebrospinal fluid nuclear and mitochondrial deoxyribonucleic acid levels in aneurysmal subarachnoid hemorrhage..J Neurosurg2013;118:13-9

[27] SairanenT,Karjalainen-LindsbergML,TurpeinenU.Evolution of cerebral tumor necrosis factor-alpha production during human ischemic stroke..Stroke2001;32:1750-8

[28] GrahamSH.Programmed cell death in cerebral ischemia..J Cereb Blood Flow Metab2001;21:99-109

[29] ReedJC.Mechanisms of apoptosis..Am J Pathol2000;157:1415-30 PMCID:PMC1885741

[30] StrounM,MauriceP,LederreyC.Neoplastic characteristics of the DNA found in the plasma of cancer patients..Oncology1989;46:318-22

[31] FournieGJ,LavalF,PourratJP.Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours..Cancer Lett1995;91:221-7

[32] LoYM,ChanLY,CocksRA.Plasma DNA as a prognostic marker in trauma patients..Clin Chem2000;46:319-23

[33] ItagakiK,LeeYT,IsalB.Mitochondrial DNA released by trauma induces neutrophil extracellular traps..PLoS One2015;10:e0120549 PMCID:PMC4361684

[34] DziedzicT.Systemic inflammation as a therapeutic target in acute ischemic stroke..Expert Rev Neurother2015;15:523-31

[35] GeigerS,StieberP,BrueningR.Nucleosomes as a new prognostic marker in early cerebral stroke..J Neurol2007;254:617-23

[36] HoldenriederS,ChanLY,KremerA.Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR..Clin Chem2005;51:1544-6

[37] LeeTH,ChrebtowV.Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma..Transfusion2001;41:276-82

[38] XiangJ,WilkinsonDA,MoosT.The choroid plexus as a site of damage in hemorrhagic and ischemic stroke and its role in responding to injury..Fluids Barriers CNS2017;14:8 PMCID:PMC5371201

[39] SerroneJC,TjahjadiM.Aneurysmal subarachnoid hemorrhage: pathobiology, current treatment and future directions..Expert Rev Neurother2015;15:367-80

[40] BronkhorstAJ,PretoriusPJ.Cell-free DNA: preanalytical variables..Clin Chim Acta2015;450:243-53

[41] SorberL,DeschoolmeesterV,LardonF.A comparison of cell-free DNA isolation kits: isolation and quantification of cell-free DNA in plasma..J Mol Diagn2017;19:162-8

[42] DevonshireAS,GutteridgeA,CowenS.Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification..Anal Bioanal Chem2014;406:6499-512 PMCID:PMC4182654

[43] PageK,ZahraN,ElshawSR.Influence of plasma processing on recovery and analysis of circulating nucleic acids..PLoS One2013;8:e77963 PMCID:PMC3799744

[44] O’ConnellGC,BarrTL.High interspecimen variability in nucleic acid extraction efficiency necessitates the use of spike-in control for accurate qPCR-based measurement of plasma cell-free DNA levels..Lab Med2017;48:332-8 PMCID:PMC5907903

[45] KrohEM,MitchellPS.Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR)..Methods2010;50:298-301 PMCID:PMC4186708

[46] YuJ,JuS.Recent advances in clinical applications of circulating cell-free DNA integrity..Lab Med2014;45:6-11

[47] HuangA,ZhouSL,HuangXW.Plasma circulating cell-free DNA integrity as a promising biomarker for diagnosis and surveillance in patients with hepatocellular carcinoma..J Cancer2016;7:1798-803 PMCID:PMC5039362

[48] WongD,AngkachatchaiV,DeSantisG.Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing..Clin Biochem2013;46:1099-104

[49] El MessaoudiS,MouliereF.Circulating cell free DNA: preanalytical considerations..Clin Chim Acta2013;424:222-30

[50] MalentacchiF,VerderioP,OrlandoC.Influence of storage conditions and extraction methods on the quantity and quality of circulating cell-free DNA (ccfDNA): the SPIDIA-DNAplas external quality assessment experience..Clin Chem Lab Med2015;53:1935-42

[51] ToroPV,BeaverJA,VanDenBergDA.Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA..Clin Biochem2015;48:993-8 PMCID:PMC4600652